Financial Statements/ESG Information - [Interim/Half-Year Report]

3D Medicines Inc. operates as a commercial-stage biopharmaceutical company. The Company focuses on the development of differentiated immuno-oncology drugs. 3D Medicines conducts businesses in China.

Interim Report 2024

Announcements and Notices - [Other - Miscellaneous]

Voluntary Announcement Increase In Shareholding By Director And Single Largest Shareholder And Senior Management

Announcements and Notices - [Revision of Published Financial Statements and Reports]

Supplemental Announcement In Relation To The 2023 Annual Report

Announcements and Notices - [Interim Results]

Interim Results Announcement
For The Six Months Ended June 30, 2024

Announcements and Notices - [Date of Board Meeting]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

3D Medicines (1244 HK)

Interim Report 2024

Voluntary Announcement Increase In Shareholding By Director And Single Largest Shareholder And Senior Management

Supplemental Announcement In Relation To The 2023 Annual Report

Interim Results Announcement For The Six Months Ended June 30, 2024

Date Of Board Meeting

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)